{"filing":{"accession_number":"0001193125-26-427224","cik":"0001640266","ticker":"VYGR","company_name":"Voyager Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-20","primary_document":"d157795d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1640266/000119312526427224/d157795d8k.htm"},"events":[{"id":36616,"run_id":33762,"accession_number":"0001193125-26-427224","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Robin Swartz was appointed President of Voyager Therapeutics effective October 20, 2026, and is expected to succeed Alfred W. Sandrock, Jr. as CEO following receipt of initial safety data in Q1 2027. This is a material executive appointment involving a clear succession plan for the chief executive role. While the disclosure also includes compensatory arrangements (equity grants, salary, severance terms), the principal disclosed action centers on Swartz taking on the President role with anticipated CEO succession, making exec_appointment the most salient classification.","company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41089,"accession_number":"0001193125-26-427224","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Robin Swartz was appointed President of Voyager Therapeutics effective October 20, 2026, and is expected to succeed Alfred W. Sandrock, Jr. as CEO following receipt of initial safety data in Q1 2027. This is a material executive appointment involving a clear succession plan for the chief executive role. While the disclosure also includes compensatory arrangements (equity grants, salary, severance terms), the principal disclosed action centers on Swartz taking on the President role with anticipated CEO succession, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T12:08:36.669110+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41089,"accession_number":"0001193125-26-427224","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Robin Swartz was appointed President of Voyager Therapeutics effective October 20, 2026, and is expected to succeed Alfred W. Sandrock, Jr. as CEO following receipt of initial safety data in Q1 2027. This is a material executive appointment involving a clear succession plan for the chief executive role. While the disclosure also includes compensatory arrangements (equity grants, salary, severance terms), the principal disclosed action centers on Swartz taking on the President role with anticipated CEO succession, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T12:08:36.669110+00:00","company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","filing_date":"2026-10-21"}]}